Course of Depressive Symptoms and Medication Adherence After Acute Coronary Syndromes An Electronic Medication Monitoring Study by Rieckmann, Nina et al.
C
A
A
N
W
N
P
o
t
w
E
p
m
t
a
w
i
p
i
t
m
N
a
S
H
P
I
g
B
a
Journal of the American College of Cardiology Vol. 48, No. 11, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pourse of Depressive Symptoms and Medication
dherence After Acute Coronary Syndromes
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OBJECTIVES We tested whether improvements in depressive symptoms precede improved adherence to
aspirin in patients with acute coronary syndromes (ACS).
BACKGROUND Depression is associated with medication nonadherence in patients with ACS, but it is
unclear whether changes in depression impact on adherence.
METHODS Electronic medication monitoring was used to measure adherence to aspirin during a
3-month period in a consecutive cohort of 172 patients (25 to 85 years) recruited within 1
week of hospitalization for ACS. Depressive symptom severity was assessed using the Beck
Depression Inventory (BDI) during hospitalization and at 1 and 3 months after hospitaliza-
tion. Adherence was defined as the percentage of days aspirin was taken as prescribed.
RESULTS Depression severity in hospital was associated with nonadherence in a gradient fashion: 15%
of non-depressed patients (BDI score 0 to 4), 29% of mildly depressed patients (BDI score
10 to 16), and 37% of patients with moderately-to-severely depressive symptoms (BDI score
16) took aspirin less than 80% of the time (p  0.03). A cross-lagged path analytic model
revealed that improvements in depressive symptoms in the first month after the ACS were
associated with improvements in adherence rates in the subsequent 2 months (standardized
direct effect 0.32, p  0.016).
CONCLUSIONS Diagnosis and treatment of depressive symptoms may improve medication adherence in
patients after ACS. (J Am Coll Cardiol 2006;48:2218–22) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.063College of Cardiology Foundation
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Yatient nonadherence complicates physicians’ attempts to
ptimize care. In patients with heart disease, poor adherence
o prescribed medications is common (1–3) and is associated
ith increased mortality and rehospitalization (1,4–6).
ight to 20% of post-acute coronary syndrome (ACS)
atients discontinue cardiac protective medications within 6
onths of hospital discharge (2).
See page 2223
Depression (with an estimated lifetime prevalence of 15%
o 20%) has been shown to be associated with poor
dherence across many patient samples, including those
ith coronary artery disease (7–9). Depression is common
n patients who experience an ACS; approximately 1 in 3
atients experiences depressive symptoms during hospital-
zation (10). Moreover, depressive symptoms during hospi-
alization are independently associated with an adverse
edical prognosis (11). Poor medication adherence has
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ccepted July 23, 2006.een proposed as a mechanism to explain why depressed
atients as compared with non-depressed patients are at
ncreased risk for mortality and other adverse outcomes after
CS (12,13). Previous data linking depression and adher-
nce, however, is derived from cross-sectional or prospective
tudies that cannot address questions of temporal sequence
nd do not take into account that in many patients,
epressive symptoms improve over the course of time
whether treated or untreated), whereas in others, symptoms
orsen (8,9). Although it is a plausible assumption, no
tudy has yet demonstrated that improvements in depressive
ymptoms lead to improvements in treatment adherence.
We used a cross-lagged panel design that included
orrelations of 3 consecutive assessments of depressive
ymptoms and medication adherence to address this ques-
ion. This design can answer which of 2 variables temporally
recedes the other. We tested whether changes in depressive
ymptoms from time 1 to time 2 precede changes in
dherence from time 2 to time 3, or whether changes in
dherence precede changes in depressive symptoms.
ETHODS
articipants. Patients with unstable angina or acute myo-
ardial infarction were recruited within 1 week of their
ospitalization for ACS. Institutional review boards of 3
niversity hospitals (Mount Sinai Hospital, New York, New
ork, and Yale–New Haven Hospital and Hospital of St.
aphael, New Haven, Connecticut) approved this study,
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December 5, 2006:2218–22 Depression and Medication Adherence After ACSnd all patients provided informed consent. Patients had to
e prescribed a daily dose of either 81 mg or 325 mg of
spirin. Patients were ineligible if they indicated the use of
eekly pill boxes and were unwilling to use an electronic
apped pill bottle instead or if they lived in nursing homes.
dditional exclusion criteria were current alcohol and/or
ubstance abuse and cognitive impairment.
epression assessment. Patients were eligible for the
tudy if they had a baseline score on the Beck Depression
nventory (BDI) (14) that was consistent with at least
ild-to-moderate depression (BDI score 10), which has
een associated with increased mortality risk after an ACS
vent (15,16). Patients were also eligible if they reported no
epression (BDI score 0 to 4). The BDI was readministered
t 1 and 3 months after the baseline score.
Three BDI groups were used to examine difference
etween non-depressed (BDI 0 to 4), mildly depressed
BDI 10 to 16), and moderately-to-severely depressed (BDI
16) patients at baseline. The BDI was used as a contin-
ous variable in the cross-lagged panel model.
dherence assessment. Upon hospital discharge, patients
ere provided with a 90-day supply of aspirin in a Medi-
ation Event Monitoring System (APREX Corp, Fremont,
Abbreviations and Acronyms
ACS acute coronary syndromes
BDI  Beck Depression InventoryFigure 1. Flowchart of participants. MEMS alifornia) bottle. This device records the date and time on
ach occasion the bottle cap is opened. The data from this
ystem were collected continuously during the 3-month
ollow-up period. Adherence was defined as the percentage
f days the bottle was opened the correct number of times
once a day). In addition to the continuous adherence score
sed in the cross-lagged panel model, a categorical adher-
nce variable was computed. Nonadherence was defined as
80% days the correct number of pills was taken. Patients
ere informed that aspirin adherence was being monitored
ut did not receive any additional counseling about
dherence.
tatistical analyses. Differences in characteristics between
on-depressed, mildly, and moderately depressed patient
roups were compared using analysis of variance for con-
inuous variables and a chi-square test for dichotomous
ariables. Logistic regression was used to examine the
ssociation between depressive symptom groups at baseline
nd medication adherence across the 3 months, controlling
or sociodemographic characteristics and the Charlson co-
orbidity index (17).
Cross-sectional and prospective relationships between
epression and adherence were tested in a cross-lagged
anel design using structural equation modeling (conducted
sing AMOS for windows 4.0 (18). Cross-lagged panel
odels examine the predictive association of 2 variables over
ime, each controlling for the effects at earlier time points.
or example, depression at time 2 is residualized by depres-medication event monitoring system.
s
t
t
m
s
a
a
l
u
R
O
s
t
(
w
0
s
n
a
m
d
I
T
w
g
e
n
p
s

t
n
c
a
9
C
t
i
e
0
b
fi
m
r
d
a
p
s
a
r
h
fi
u
(
0
D
D
m
w
m
d
m
t
i
s
H
T
A
F
W
H
S
C
* alysis o
F
i
2220 Rieckmann et al. JACC Vol. 48, No. 11, 2006
Depression and Medication Adherence After ACS December 5, 2006:2218–22ion at time 1 and thus represents change in depression from
ime 1 to time 2.
A model was tested that included: 1) correlations among
he 3 continuous depression measures and the 3 adherence
easures over time (stability of each variable); 2) cross-
ectional correlations between depression and adherence;
nd 3) cross-(time-) lagged correlations between depression
nd adherence (and changes in these variables). Maximum
ikelihood estimation was used to estimate overall model fit
sing the chi-square goodness-of-fit statistic.
ESULTS
f 274 eligible patients, 205 (74.8%) consented to the
tudy. Refusers (those not consenting and those not willing
o switch from a pill box) had significantly higher mean
SD) levels of depressive symptoms on the BDI compared
ith consenting patients (11.0  9.8 vs. 8.2  8.7; p 
.05). A total of 33 patients (16.1%) did not complete the
tudy (Fig. 1). Patients who did not complete the study did
ot significantly differ from patients who did on age, gender,
nd depressive symptom severity (all p  0.35). Sociode-
ographic characteristics of patients who participated are
isplayed in Table 1.
n-hospital depression and adherence after discharge.
he mean (SD) number of days aspirin was monitored
as 83.0 13.6 and did not differ between the 3 depression
roups. Depression severity was associated with nonadher-
nce in a gradient fashion (Fig. 2): 15% (14 of 93) of
on-depressed patients, 29% (14 of 49) of mildly depressed
atients, and 37% (11 of 30) of patients with moderate-to-
evere depressive symptoms were nonadherent (chi-square
7.4, p  0.03). Compared with non-depressed patients,
hose with severe depressive symptoms had a 3-fold odds of
ot taking medications as prescribed (odds ratio 3.3; 95%
onfidence interval 1.3 to 8.3). This association was stronger
fter adjustment for potential confounders (odds ratio 3.7;
5% confidence interval 1.3 to 10.6).
hanges in depression and changes in adherence over
ime. Figure 3 displays the cross-lagged panel model relat-
ng changes in depressive symptoms to changes in adher-
nce over time (overall model fit: chi-square  9.74, p 
.021). As expected, higher depressive symptom scores at
aseline were associated with lower adherence within the
able 1. Baseline Sample Characteristics*
Variable
Non-Depressed
(n  93)
Mildly
(n
ge, yrs 59.7  11.6 60.8
emale, n (%) 35 (37.6) 26
hite, n (%) 79 (84.9) 46
ispanic, n (%) 1 (1.1) 3
chooling, yrs 13.9  2.6 13.6
harlson Comorbidity Index 1.2  1.5 1.2
Plus-minus values are mean  SD. †Continuous variables were compared using anrst 2 weeks after discharge.
4
(Changes in depressive symptoms from baseline (T1) to 1
onth (T2) were inversely related to changes in adherence
ates from 1 month (T2) to 3 months (T3; standardized
irect effect 0.32, p  0.016), indicating that medication
dherence increased in patients after depression had im-
roved, and it decreased in patients whose depressive
ymptoms had worsened. To describe the size of this effect,
1 standard deviation decrease on the BDI (5.9 points)
esulted in a one-third standard deviation increase in ad-
erence (6.7%). In contrast, changes in adherence from the
rst week after discharge (T1) to 1 month (T2) were
nrelated to changes in depressive symptoms from 1 month
T2) to 3 months (T3) (standardized direct effect 0.02; p 
.70).
ISCUSSION
epression is a burdensome psychosocial problem and a risk
arker for mortality with a high prevalence among patients
ith ACS (10,11,15,16). It has been associated with poor
edication adherence in patients with coronary artery
isease (8,9), but no study has assessed whether improve-
ents in depressive symptoms result in improved medica-
ion adherence.
We found a gradient relation between the severity of
n-hospital depressive symptoms and rates of nonadherence,
imilar to findings from the Heart and Soul Study (9).
owever, in our sample rates of nonadherence were approx-
essed
)
Moderately to Severely Depressed
(n  30) p Value†
.2 55.8  9.2 0.18
) 16 (53.3) 0.12
) 24 (80.0) 0.17
4 (13.3) 0.02
13.0  3.5 0.32
1.7  1.6 0.19
f variance. Categorical variables were compared with chi-square statistics.
igure 2. Proportion of nonadherent (aspirin taken80% of days) patients
n 3 groups: non-depressed (Beck Depression Inventory [BDI] score 0 toDepr
 49
 14
(53.1
(93.9
(6.1)
 3.1
 1.2), mildly depressed (BDI 10 to 16), and moderately to severely depressed
BDI 16).
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December 5, 2006:2218–22 Depression and Medication Adherence After ACSmately 3 times greater. One major difference between the 2
tudies is that we used an electronic assessment of medica-
ion adherence, whereas the Heart and Soul Study assessed
onadherence by self-report, suggesting that patients may
verestimate their level of adherence.
We monitored adherence to only 1 medication—
spirin—whereas the self-report questions in the Heart
nd Soul Study asked about all medications. We have no
nformation regarding adherence to medication other
han aspirin, nor did we take into account the total
umber of medications patients were prescribed. How-
ver, this is unlikely to explain higher nonadherence rates
n our study. Patients had a simple regimen (1 tablet per
ay), and the monitored drug (aspirin) has few side
ffects, both of which should predict better, not worse,
dherence.
Our study might underestimate nonadherence rates in
ost-ACS patients because patients who refused participa-
ion were significantly more depressed. Patients with BDI
cores of 5 to 9 at baseline were excluded from the study,
hich might have yielded inflated coefficients in our anal-
sis. Adherence rates in our sample might not generalize to
atients who use weekly pill boxes because we excluded
hose patients.
In this observational study, we showed that improve-
ents in depressive symptoms were associated with subse-
uent improvements in adherence rates in a relatively short
eriod of time. This has potential implications for future
dherence interventions. Although medication adherence
as been the target of a large number of interventions, these
ave, for the most part, not been very effective or were very
omplex (19,20). It is not known why these interventions
end to have small effects on improving adherence and
linical outcomes; perhaps treating depression first will
how promise in future interventions designed to increase
igure 3. Cross-lagged panel model testing the relationship between
yndromes.edication adherence.
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